EIRx Biologics

EIRx

Developing a groundbreaking cell-based therapy
targeting Duchenne Muscular Dystrophy.

About Us

Our Science

About EIRx

Why you should know about us.

Developing a groundbreaking cell-based therapy targeting Duchenne Muscular Dystrophy, the most severe form of muscular dystrophy characterized by muscle degeneration and premature mortality. The company’s non-viral vector system is designed to deliver the full-length dystrophin gene, representing a rational, scalable approach to restoring functional dystrophin expression in affected muscle t issue.

Overview of DMD:

Individuals with DMD lack or produce insufficient dystrophin, leading to muscle cell damage and replacement with fat and fibrotic tissue over time. However, innovative therapies targeting the underlying genetic cause offer hope for improved outcomes.

These advancements hold promise for enhancing the prognosis and quality of life for individuals affected by DMD, offering newfound optimism for managing this debilitating condition.

1 in 3500 to 5000 males

Affected by DMD

Ages 3-5

Symptoms will first appear

Age 12

Many patients will need wheelchair assistance.

$18.1B

Market evaluation by 2030

https://www.coherentmarketinsights.com

Our Science

A Pre-clinical Cell Therapy Company with Advanced Capabilities.

• Caused by a variety of mutations in the dystrophin gene
• No definitive cure exists
• Current treatments have safety issues and limited efficacy

Stages

Early Ambulatory

Late Ambulatory

Early Non-Ambulatory

Late Non-Ambulatory

Early Ambulatory

Late Ambulatory

Early Non-Ambulatory

Late Non-Ambulatory

Early Ambulatory

Late Ambulatory

Early Non-Ambulatory

Late Non-Ambulatory

5-7 Years

8-11 Years

Early Teens

Teens

Teens to Twenties

Impact

Between ages 5 and 7, early signs became noticeable, including motor delays, enlarged calves, toe walking, and increasing difficulty standing up from a supine position or climbing stairs.

5-7 Years

8-11 Years

Early Teens

Teens

Teens to Twenties

Impact

Between ages 5 and 7, early signs became noticeable, including motor delays, enlarged calves, toe walking, and increasing difficulty standing up from a supine position or climbing stairs.

5-7 Years

8-11 Years

Early Teens

Teens

Teens to Twenties

Impact

Between ages 5 and 7, early signs became noticeable, including motor delays, enlarged calves, toe walking, and increasing difficulty standing up from a supine position or climbing stairs.

Current Landscape

Limitations in Current DMD Therapies.

DRUG THERAPY

Palliative care
Adverse effects
Toxicity
Limited Response

GENE THERAPY

Vector limitations
Immune response
Short term response
Toxicity

CELL THERAPY

Limited Response
Insufficient gene dose

Situations to address

Cell Engineering System to Address Current Treatment Limitations.

Licensed from CG Bioengineering (CGB), EIRx is Utilizing The Human Synthetic Chromosome* (hSynC)

AAV vector

May integrate into host genome

Viral/potential immune response

Limited repeated dosing

Therapeutic efficacy influenced by vector instability

hSync - Synthetic Chromosome

Carrying capacity of >300,000 base pairs

Non-integrating (safety)

Non-viral, stable

Safety, does not require repeated reintroduction

Stable gene expression

Moving forward

The Next Generation of Duchenne Muscular Dystrophy (DMD) Cell Therapy.

DMD-hSynC

Demonstrated ability to carry entire DMD gene for full dystrophin (Dp427) for muscle fiber integrity AND DMD isomer (Dp71ab) for muscle satellite cell activation and proliferation

Validated expression of DMD gene (Dp427) from hSynC in vivo

Universal therapy for all dystrophin mutations

Does not require immunosuppression

Non-viral delivery

DMD-hSynC

Market Research

Research

Emerging DMD Market Primed
for Disruption.

Emerging DMD Market Primed for Disruption

DMD is a space with great untapped potential, a fact underlined by the limited available product

it’s gratifying to see something approved after all these years, the current system is not perfect by any means

An example of a potential strategy would be to use stem cells carrying human artificial chromosomes containing multiple cDNAs encoding the missing protein Berry SE (2015) Stem Cells Translational Medicine 4:91-98

Advisors

Alistair Duncan BSc, CPA-CA

Lead Advisor

Alistair Duncan BSc, CPA-CA

Lead Advisor

Mr. Duncan, currently serves as Lead Director on the Board of Directors of CG Bioengineering.
As a seasoned biotechnology entrepreneur with over 25 years of experience as an executive, director, investor, and advisor. He is the Co-founder, President, and CEO of viDA Therapeutics Inc., leading the development of innovative therapies for inflammatory and age-related diseases. Throughout his career, he has played a key role in biotech ventures, focusing on corporate strategy, fundraising, and commercialization. His expertise spans from early-stage startups to established firms, driving innovation and business growth in the biotechnology industry.

Mr. Duncan, currently serves as Lead Director on the Board of Directors of CG Bioengineering. As a seasoned biotechnology entrepreneur with over 25 years of experience as an executive, director, investor, and advisor. He is the Co-founder, President, and CEO of viDA Therapeutics Inc., leading the development of innovative therapies for inflammatory and age-related diseases. Throughout his career, he has played a key role in biotech ventures, focusing on corporate strategy, fundraising, and commercialization. His expertise spans from early-stage startups to established firms, driving innovation and business growth in the biotechnology industry.

Partnership

Meet our Partner Company.

Meet our
Partner Company.

Learn more about our Partners at CG BIOENGINEERING

Learn more about our Partners at
CG BIOENGINEERING

The leaders in the development of novel hSynC-based cell therapies and seek to create transformative treatments for unaddressed or under-addressed human genetic diseases.

🔹Creating Transformative Gene Based Medicines

Creating Transformative Gene Based Medicines

Learn More

Learn More

News & Events

Explore the latest discoveries, announcements, and industry insights.

CGB-EIRx License Agreement

November 2025

Download

CGB-EIRx License Agreement

November 2025

Download

CGB-EIRx License Agreement

November 2025

Download

CGB Defense TechConnect

November 2025

Download

CGB Defense TechConnect

November 2025

Download

CGB Defense TechConnect

November 2025

Download

ASGCT DMD Poster

November 2024

Download

ASGCT DMD Poster

November 2024

Download

ASGCT DMD Poster

November 2024

Download

Contact Us

Get in Touch with Us Today!

Email Us

Reach out to our team for quick assistance.

aduncan@cgbioengineering.com

Email Us

Reach out to our team for quick assistance.

aduncan@cgbioengineering.com

Community Outreach

Learn More About Muscular Dystropy

CureDuchenne

Muscular Dystrophy Association

About EIRx

Why you should know about us.

Overview of DMD:

Our Science

A Pre-clinical Cell Therapy Company with Advanced Capabilities.

Stages

Early Ambulatory

Late Ambulatory

Early Non-Ambulatory

Late Non-Ambulatory

Early Ambulatory

Late Ambulatory

Early Non-Ambulatory

Late Non-Ambulatory

Early Ambulatory

Late Ambulatory

Early Non-Ambulatory

Late Non-Ambulatory

5-7 Years

8-11 Years

Early Teens

Teens

Teens to Twenties

Impact

5-7 Years

8-11 Years

Early Teens

Teens

Teens to Twenties

Impact

5-7 Years

8-11 Years

Early Teens

Teens

Teens to Twenties

Impact

Current Landscape

Limitations in Current DMD Therapies.

DRUG THERAPY

DRUG THERAPY

Palliative careAdverse effectsToxicityLimited Response

Palliative careAdverse effectsToxicityLimited Response

GENE THERAPY

GENE THERAPY

Vector limitationsImmune responseShort term responseToxicity

Vector limitationsImmune responseShort term responseToxicity

CELL THERAPY

CELL THERAPY

Limited ResponseInsufficient gene dose

Limited ResponseInsufficient gene dose

Situations to address

Cell Engineering System to Address Current Treatment Limitations.

AAV vector

May integrate into host genome

May integrate into host genome

Viral/potential immune response

Viral/potential immune response

Limited repeated dosing

Limited repeated dosing

Therapeutic efficacy influenced by vector instability

Therapeutic efficacy influenced by vector instability

hSync - Synthetic Chromosome

Carrying capacity of >300,000 base pairs

Carrying capacity of >300,000 base pairs

Non-integrating (safety)

Non-integrating (safety)

Non-viral, stable

Non-viral, stable

Safety, does not require repeated reintroduction

Safety, does not require repeated reintroduction

Stable gene expression

Stable gene expression

Moving forward

The Next Generation of Duchenne Muscular Dystrophy (DMD) Cell Therapy.

DMD-hSynC

Demonstrated ability to carry entire DMD gene for full dystrophin (Dp427) for muscle fiber integrity AND DMD isomer (Dp71ab) for muscle satellite cell activation and proliferation

Demonstrated ability to carry entire DMD gene for full dystrophin (Dp427) for muscle fiber integrity AND DMD isomer (Dp71ab) for muscle satellite cell activation and proliferation

Validated expression of DMD gene (Dp427) from hSynC in vivo

Validated expression of DMD gene (Dp427) from hSynC in vivo

Universal therapy for all dystrophin mutations

Palliative care
Adverse effects
Toxicity
Limited Response

Palliative care
Adverse effects
Toxicity
Limited Response

Vector limitations
Immune response
Short term response
Toxicity

Vector limitations
Immune response
Short term response
Toxicity

Limited Response
Insufficient gene dose

Limited Response
Insufficient gene dose

Emerging DMD Market Primed
for Disruption.

Meet our
Partner Company.

Learn more about our Partners at
CG BIOENGINEERING